Michelle Petri, MD MPH

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    MedShr
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    03/31/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Merck EMD Serono
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Nexstone Immunology
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Nimbus Lakshmi
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    07/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Proviant
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Regeneron Pharmaceuticals
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Sanofi
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    09/30/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Seismic Therapeutic
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Sinomab Biosciences
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Takeda
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024

Pages

Return to 2024 Inova Fairfax MGR (Enduring Material): Update on SLE Classification, Treatment, and Complications